EYPT
Price
$5.91
Change
+$0.06 (+1.03%)
Updated
May 13 closing price
Capitalization
406.68M
77 days until earnings call
NTLA
Price
$8.32
Change
-$0.23 (-2.69%)
Updated
May 13 closing price
Capitalization
861.81M
78 days until earnings call
Ad is loading...

EYPT vs NTLA

Header iconEYPT vs NTLA Comparison
Open Charts EYPT vs NTLABanner chart's image
EyePoint Pharmaceuticals
Price$5.91
Change+$0.06 (+1.03%)
Volume$497.44K
Capitalization406.68M
Intellia Therapeutics
Price$8.32
Change-$0.23 (-2.69%)
Volume$3.43M
Capitalization861.81M
EYPT vs NTLA Comparison Chart
Loading...
EYPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EYPT vs. NTLA commentary
May 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EYPT is a Hold and NTLA is a Hold.

Ad is loading...
COMPARISON
Comparison
May 14, 2025
Stock price -- (EYPT: $5.91 vs. NTLA: $8.32)
Brand notoriety: EYPT and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EYPT: 66% vs. NTLA: 95%
Market capitalization -- EYPT: $406.68M vs. NTLA: $861.81M
EYPT [@Biotechnology] is valued at $406.68M. NTLA’s [@Biotechnology] market capitalization is $861.81M. The market cap for tickers in the [@Biotechnology] industry ranges from $295.2B to $0. The average market capitalization across the [@Biotechnology] industry is $2.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EYPT’s FA Score shows that 1 FA rating(s) are green whileNTLA’s FA Score has 1 green FA rating(s).

  • EYPT’s FA Score: 1 green, 4 red.
  • NTLA’s FA Score: 1 green, 4 red.
According to our system of comparison, EYPT is a better buy in the long-term than NTLA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EYPT’s TA Score shows that 4 TA indicator(s) are bullish while NTLA’s TA Score has 7 bullish TA indicator(s).

  • EYPT’s TA Score: 4 bullish, 6 bearish.
  • NTLA’s TA Score: 7 bullish, 2 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than EYPT.

Price Growth

EYPT (@Biotechnology) experienced а -5.44% price change this week, while NTLA (@Biotechnology) price change was +14.76% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.36%. For the same industry, the average monthly price growth was +9.41%, and the average quarterly price growth was -8.48%.

Reported Earning Dates

EYPT is expected to report earnings on Jul 30, 2025.

NTLA is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+0.36% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($862M) has a higher market cap than EYPT($407M). EYPT YTD gains are higher at: -20.671 vs. NTLA (-28.645). EYPT has higher annual earnings (EBITDA): -144.55M vs. NTLA (-530.8M). NTLA has more cash in the bank: 504M vs. EYPT (318M). EYPT has less debt than NTLA: EYPT (24.1M) vs NTLA (119M). EYPT has higher revenues than NTLA: EYPT (56M) vs NTLA (45.6M).
EYPTNTLAEYPT / NTLA
Capitalization407M862M47%
EBITDA-144.55M-530.8M27%
Gain YTD-20.671-28.64572%
P/E RatioN/AN/A-
Revenue56M45.6M123%
Total Cash318M504M63%
Total Debt24.1M119M20%
FUNDAMENTALS RATINGS
EYPT vs NTLA: Fundamental Ratings
EYPT
NTLA
OUTLOOK RATING
1..100
156
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
29
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9492
PRICE GROWTH RATING
1..100
6363
P/E GROWTH RATING
1..100
16100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (29) in the Biotechnology industry is in the same range as EYPT (61) in the Pharmaceuticals Major industry. This means that NTLA’s stock grew similarly to EYPT’s over the last 12 months.

NTLA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as EYPT (100) in the Pharmaceuticals Major industry. This means that NTLA’s stock grew similarly to EYPT’s over the last 12 months.

NTLA's SMR Rating (92) in the Biotechnology industry is in the same range as EYPT (94) in the Pharmaceuticals Major industry. This means that NTLA’s stock grew similarly to EYPT’s over the last 12 months.

NTLA's Price Growth Rating (63) in the Biotechnology industry is in the same range as EYPT (63) in the Pharmaceuticals Major industry. This means that NTLA’s stock grew similarly to EYPT’s over the last 12 months.

EYPT's P/E Growth Rating (16) in the Pharmaceuticals Major industry is significantly better than the same rating for NTLA (100) in the Biotechnology industry. This means that EYPT’s stock grew significantly faster than NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EYPTNTLA
RSI
ODDS (%)
Bearish Trend 1 day ago
89%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
78%
Momentum
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
79%
MACD
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
76%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
78%
Advances
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 7 days ago
78%
Declines
ODDS (%)
Bearish Trend 8 days ago
89%
Bearish Trend 9 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
84%
Aroon
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
87%
View a ticker or compare two or three
Ad is loading...
EYPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TEMUX14.67N/A
N/A
Morgan Stanley Pathway Em Mkts Eq
GSTSX9.76N/A
N/A
Goldman Sachs Strategic Growth Svc
FAPCX17.89N/A
N/A
Fidelity Intl Cptl Apprec K6
GEBAX10.72N/A
N/A
Goldman Sachs ESG Em Mkts Eq A
MKVCX14.94N/A
N/A
MFS International Large Cap Value C

EYPT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EYPT has been loosely correlated with OCUL. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if EYPT jumps, then OCUL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EYPT
1D Price
Change %
EYPT100%
+1.03%
OCUL - EYPT
59%
Loosely correlated
-5.28%
LYRA - EYPT
58%
Loosely correlated
+0.21%
ATHE - EYPT
54%
Loosely correlated
-5.47%
NTLA - EYPT
52%
Loosely correlated
-2.69%
RXRX - EYPT
52%
Loosely correlated
-2.80%
More

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with VCYT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
-2.69%
VCYT - NTLA
69%
Closely correlated
-4.71%
CRSP - NTLA
66%
Loosely correlated
+4.49%
BEAM - NTLA
64%
Loosely correlated
-1.04%
RCKT - NTLA
62%
Loosely correlated
-5.50%
RXRX - NTLA
60%
Loosely correlated
-2.80%
More